Genscript Biotech (1548) Price & Analysis

Compare

8 Followers

1548 Stock Chart & Stats

Day’s Range― - ―

52-Week RangeHK$8.88 - HK$19.40

Previous CloseN/A

Volume5.33M

Average Volume (3M)12.12M

Market Cap

$36.41B

Enterprise ValueHK$26.12B

Total Cash (Recent Filing)$938.36M

Total Debt (Recent Filing)$548.52M

Price to Earnings (P/E)1.0

Beta1.15

Next Earnings

Mar 27, 2026

EPS Estimate

-0.08

Last Dividend Ex-Date

Jun 05, 2017

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.17

Shares Outstanding2,185,099,900

10 Day Avg. Volume6,443,664

30 Day Avg. Volume12,119,956

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)0.64

Price to Sales (P/S)4.64

P/FCF Ratio-38.16

Enterprise Value/Market Cap0.72

Enterprise Value/Revenue47.34

Enterprise Value/Gross Profit91.42

Enterprise Value/Ebitda65.75

Forecast

1Y Price Target

$23.96

Price Target Upside43.07% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Genscript Biotech News

Genscript Biotech Reports Strong CARVYKTI® Sales in Q3 2025

Genscript Biotech ( ($HK:1548) ) has shared an update. Genscript Biotech Corporation announced that its associate, Legend Biotech,...

1m ago

Genscript Biotech’s ProBio Receives Significant Sublicense Revenue Boost

Genscript Biotech ( ($HK:1548) ) has provided an announcement. Genscript Biotech Corporation announced that its subsidiary, ProBio, received...

3h ago

Genscript Biotech Grants Share Awards to Boost Employee Engagement

Genscript Biotech ( ($HK:1548) ) has provided an update. Genscript Biotech Corporation announced the grant of 774,960 Share...

23d ago

GenScript Biotech’s Earnings Call Highlights Robust Growth

Genscript Biotech Corporation (($HK:1548)) has held its Q2 earnings call. Read on for the main highlights of the...

1M ago

Genscript Biotech Reports Strong Revenue Growth Amid Strategic Investments

Genscript Biotech Corporation ( ($GNNSF) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

Genscript Biotech Reports Strong Revenue and Profit Growth in H1 2025

Genscript Biotech ( ($HK:1548) ) has issued an announcement. Genscript Biotech Corporation reported significant financial growth in its...

2M ago

Genscript Biotech’s Associate Legend Biotech Reports Q2 2025 Financial Results

Genscript Biotech ( ($HK:1548) ) has shared an announcement. Genscript Biotech Corporation announced that its associate, Legend Biotech...

2M ago

Genscript Biotech Schedules Board Meeting for Interim Results Review

An announcement from Genscript Biotech ( ($HK:1548) ) is now available. Genscript Biotech Corporation has announced a board...

2M ago

Genscript Biotech Projects Significant Profit Growth for H1 2025

An announcement from Genscript Biotech ( ($HK:1548) ) is now available. Genscript Biotech Corporation has announced a significant...

3M ago

Legend Biotech Reports Strong Sales for CARVYKTI® in Q2 2025

Genscript Biotech ( ($HK:1548) ) has shared an update. Legend Biotech, an associate of Genscript Biotech, announced that...

3M ago

Legend Biotech announces cilta-cel approval in China for multiple myeloma

Legend Biotech (LEGN), a subsidiary of GenScript Biotech Corporation (GNNSF), announced they have received approval from the China...

1y ago

LEGN

Twist extends rally as Wall Street sees opportunity amid GenScript scrutiny

Shares of Twist Bioscience (TWST) are on the rise again on Wednesday as U.S. lawmakers scrutinize competitor GenScript...

1y ago

DHR

TMO

Genscript Biotech initiated with a Buy at Goldman Sachs

Goldman Sachs initiated coverage of Genscript Biotech with a Buy rating and HK$29.34 price target, implying 31% upside...

2y ago

Genscript Biotech initiated with an Outperform at CICC

CICC initiated coverage of Genscript Biotech with an Outperform rating and HK$31.20 price target. Published first on TheFly...

3y ago

GNNSF

1548 FAQ

What was Genscript Biotech’s price range in the past 12 months?

Genscript Biotech lowest stock price was HK$8.88 and its highest was HK$19.40 in the past 12 months.

What is Genscript Biotech’s market cap?

Genscript Biotech’s market cap is $36.41B.

When is Genscript Biotech’s upcoming earnings report date?

Genscript Biotech’s upcoming earnings report date is Mar 27, 2026 which is in 164 days.

How were Genscript Biotech’s earnings last quarter?

Genscript Biotech released its earnings results on Aug 17, 2025. The company reported -HK$0.171 earnings per share for the quarter, missing the consensus estimate of HK$0.622 by -HK$0.793.

Is Genscript Biotech overvalued?

According to Wall Street analysts Genscript Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Genscript Biotech pay dividends?

Genscript Biotech pays a Notavailable dividend of HK$0.012 which represents an annual dividend yield of N/A. See more information on Genscript Biotech dividends here

What is Genscript Biotech’s EPS estimate?

Genscript Biotech’s EPS estimate is -0.08.

How many shares outstanding does Genscript Biotech have?

Genscript Biotech has 2,185,099,900 shares outstanding.

What happened to Genscript Biotech’s price movement after its last earnings report?

Genscript Biotech reported an EPS of -HK$0.171 in its last earnings report, missing expectations of HK$0.622. Following the earnings report the stock price went down -5.185%.

Which hedge fund is a major shareholder of Genscript Biotech?

Currently, no hedge funds are holding shares in HK:1548

Genscript Biotech Stock Smart Score

Neutral

Fundamentals

Return on Equity

-6.09%

Trailing 12-Months

Asset Growth

63.11%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Genscript Biotech

Genscript Biotech (1548) is a leading global biotechnology company that specializes in providing gene synthesis, peptide synthesis, and other related services to the life sciences and pharmaceutical industries. The company operates in several sectors, including synthetic biology, drug discovery, and research services, offering a wide range of core products and services such as custom DNA and RNA synthesis, antibody development, protein production, and gene editing technologies. Genscript aims to empower scientists and researchers by providing high-quality, reliable, and innovative solutions to accelerate life sciences research and therapeutic development.

Genscript Biotech (1548) Earnings & Revenues

Historic Earnings Reports

1548 Company Deck

1548 Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant revenue growth across all segments, strong performance of Legend Biotech's CAR-T product, and a robust cash position. However, the Group faced challenges with net losses due to Legend Biotech, temporary impacts on gross margins, and capacity issues in ProBio. Despite these challenges, the positive achievements and growth outweigh the difficulties.View all HK:1548 earnings summaries

1548 Stock 12 Month Forecast

Average Price Target

HK$23.96

▲(43.07% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"HK$9","22":"HK$22","35":"HK$35","15.5":"HK$15.5","28.5":"HK$28.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24.0026143346592,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.964768674,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$23.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.0026143346592,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,15.5,22,28.5,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.72,17.28020110266609,17.840402205332182,18.400603307998274,18.96080441066437,19.52100551333046,20.081206615996553,20.641407718662645,21.201608821328737,21.761809923994832,22.322011026660924,22.882212129327016,23.442413231993108,{"y":24.0026143346592,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.72,17.277289898,17.834579796,18.391869694,18.949159591999997,19.506449489999998,20.063739388,20.621029286,21.178319184,21.735609081999996,22.292898979999997,22.850188877999997,23.407478775999998,{"y":23.964768674,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.72,17.28020110266609,17.840402205332182,18.400603307998274,18.96080441066437,19.52100551333046,20.081206615996553,20.641407718662645,21.201608821328737,21.761809923994832,22.322011026660924,22.882212129327016,23.442413231993108,{"y":24.0026143346592,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34.5,"date":1640995200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":34.5,"date":1640995200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.38,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.5,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.64,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.78,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.92,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.8,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":16.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.73,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.72,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >